GET DAILY SIGNALSZimmer Biomet (ZBH) vs Stryker (SYK): Recent Results Highlight Diverging Momentum
Key Takeaways
- Zimmer Biomet beat third-quarter earnings estimates and raised its full-year 2026 outlook, while Stryker missed estimates and lowered guidance.
- ZBH shares surged to 52-week highs after its latest report, whereas SYK shares have underperformed the broader market year to date.
- Stryker is working through a CEO succession, cybersecurity recovery, and softer hip-and-knee procedure demand, while Zimmer Biomet is seeing broad-based growth offsetting isolated knee weakness.
- Tickeron AI Verdict: Based on trend consistency, guidance momentum, and relative market positioning, Tickeron's AI would currently favor ZBH over SYK.
- For deeper context on each name, explore SYK Major News and SYK Today's Price Move, plus ZBH Major News and ZBH Today's Price Move.
- To see how automated systems are positioning across the market, explore the Trending AI Robots page.
Setting the Stage for Two Orthopedic Leaders
Stryker Corporation (SYK) and Zimmer Biomet Holdings (ZBH) stand out as major players in orthopedic and medical technology, with overlapping exposure to implants, robotics, and surgical equipment. A side-by-side look at the two feels especially relevant for healthcare investors focused on device demand, procedure volumes, and advances like robotic-assisted surgery. Even though they compete in the same space, their recent paths have moved in noticeably different directions, which offers useful perspective for evaluating relative performance and positioning. This review covers recent business updates, momentum factors, and risks to gauge which setup appears more constructive at the moment. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
Stryker’s Recent Challenges and Business Profile
Stryker designs and manufactures medical devices across its MedSurg and Neurotechnology and Orthopaedics segments. The lineup covers hip and knee implants, trauma and extremities products, endoscopy systems, hospital beds, and the Mako robotic surgery platform. Lately the stock has come under pressure from several factors, including a March cybersecurity incident that briefly disrupted ordering, shipping, and manufacturing, along with a July enterprise-software (SAP) implementation that affected commercial execution.
The company’s most recent quarterly results fell short of analyst expectations, with softer hip-and-knee procedure demand, peripheral vascular supply constraints, and commercial execution issues contributing to the shortfall. Management lowered full-year organic sales growth guidance in response, which weighed on sentiment. Stryker is also managing a planned CEO succession, with Kevin Lobo moving to executive chairman at the start of 2027. Even with these near-term pressures, the company holds a diversified portfolio, solid margins, and a strong position in operating-room equipment that supports its longer-term position. From what I see, these elements remain important anchors despite the current headwinds.
Zimmer Biomet’s Positive Momentum and Growth Drivers
Zimmer Biomet is a global leader in musculoskeletal healthcare, offering products across knee and hip reconstruction, sports medicine, extremities, trauma, and a growing technology and data segment that includes the ROSA and TMINI robotic systems. The company reports across four categories: Knees, Hips, S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic), and Technology & Data, Bone Cement and Surgical.
Recent results have been favorable. The latest quarterly report exceeded expectations, with revenue and adjusted earnings per share beating consensus. Two-thirds of the business grew at upper-single-digit or double-digit rates, led by hips, S.E.T., and technology and data. Management raised full-year 2026 organic constant-currency sales growth and adjusted EPS guidance, and the stock moved toward 52-week highs. The company continues to handle a multi-quarter U.S. sales force transition (Project Optima) that has affected its knee franchise, yet catalysts such as the Monogram robotic system—now expected in the first half of 2027—have strengthened the outlook. I’m watching this closely because the guidance lift stands out against the sector backdrop.
Head-to-Head: Momentum, Scale, and Risks
The clearest divergence shows up in near-term momentum. ZBH is in a positive earnings cycle, raising guidance while expanding beyond core joint reconstruction into robotics, data, and faster-growing areas. SYK, on the other hand, is navigating operational disruptions, a leadership transition, and slower large-joint procedure growth.
From a scale standpoint, Stryker is the larger and more diversified business, with a market capitalization roughly five times that of Zimmer Biomet and historically stronger revenue growth and margins. Its MedSurg franchise adds exposure outside orthopedics, which reduces dependence on any single procedure category. Zimmer Biomet, however, currently presents the clearer catalyst picture: an accelerating product cycle in hips and technology, an upcoming robotic platform, and a sales force restructuring that management expects to improve efficiency over time.
Risk profiles also differ. Stryker’s recent issues are partly transitory yet have led to a guidance cut and negative price reaction. Zimmer Biomet faces execution risk around its sales force transition and ongoing knee competition, but the market has responded positively to its improving fundamentals. On relative performance, ZBH has shown stronger recent price momentum, while SYK trades below its 52-week high and has lagged the market year to date. One thing that stands out is how guidance direction has influenced sentiment in each case.
AI Verdict on the Two Names
Based on observable factors, Tickeron’s AI would likely favor ZBH over SYK in the current environment. The assessment reflects positive earnings momentum, an upwardly revised full-year outlook, and a stock price that has reacted favorably to recent catalysts. While Stryker retains a stronger long-term franchise and greater diversification, its recent guidance reduction, softer procedure demand, and operational disruptions affect trend consistency and near-term sentiment. No single metric guarantees future performance, but the balance of momentum, guidance direction, and market reaction currently tilts toward ZBH.
Integrating AI Tools Into Portfolio Review
In my own process I occasionally reference Tickeron’s AI Trend Prediction Engine when comparing names like these to gauge how quantitative signals align with fundamental developments. It provides an additional lens for evaluating trend consistency without replacing traditional analysis. The platform’s outputs help frame probabilistic scenarios across a range of market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Momentum Indicator for SYK turns positive, indicating new upward trend
SYK saw its Momentum Indicator move above the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In 54 of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at 60%.
Technical Analysis (Indicators)
Bullish Trend Analysis
SYK moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SYK crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 45%.
Following a +10.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYK advanced for three days, in 174 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
The Aroon Indicator entered an Uptrend today. In 128 of 258 cases where SYK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.
Bearish Trend Analysis
The 10-day RSI Indicator for SYK moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 22 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 58%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 59 cases where SYK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 51%.
The Moving Average Convergence Divergence Histogram (MACD) for SYK turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 22 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 49%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 50%.
SYK broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. SYK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 68 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.211) is normal, around the industry mean (4.142). P/E Ratio (33.491) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (11.253). Dividend Yield (0.011) settles around the average of (0.011) among similar stocks. P/S Ratio (4.259) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of reconstructive, medical and surgical, and neurotechnology and spine products
Industry MedicalNursingServices
Advertisement